These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 15727721)

  • 1. Reversal of atherosclerosis with aggressive lipid lowering.
    Farmer JA
    Curr Atheroscler Rep; 2005 Mar; 7(2):86-7. PubMed ID: 15727721
    [No Abstract]   [Full Text] [Related]  

  • 2. Aggressive lipid-lowering regimen halts CHD progression.
    Geriatrics; 2004 Jan; 59(1):44. PubMed ID: 14755869
    [No Abstract]   [Full Text] [Related]  

  • 3. C-reactive protein levels and outcomes after statin therapy.
    Clearfield M
    Curr Atheroscler Rep; 2006 Jan; 8(1):8-9. PubMed ID: 16455006
    [No Abstract]   [Full Text] [Related]  

  • 4. [Regarding LDL cholesterol: the lower, the better (interview by Dr. Dirk Einecke)].
    Nissen S
    MMW Fortschr Med; 2004 Mar; 146(13):65. PubMed ID: 15219143
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
    Nissen SE
    Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive versus moderate lipid lowering with statins in acute coronary syndromes.
    Farmer JA
    Curr Atheroscler Rep; 2005 Mar; 7(2):85-6. PubMed ID: 15727720
    [No Abstract]   [Full Text] [Related]  

  • 7. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lowering of cholesterol. What role is played by the choice of statins?].
    März W
    MMW Fortschr Med; 2004 Sep; 146(35-36):55. PubMed ID: 15540544
    [No Abstract]   [Full Text] [Related]  

  • 9. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [First comparison of 2 statins shows: only radical LDL lowering stops coronary atherosclerosis].
    Einecke D
    MMW Fortschr Med; 2003 Dec; 145(51-52):38. PubMed ID: 14974329
    [No Abstract]   [Full Text] [Related]  

  • 11. [Maintaining the full benefit of statins. Therapy start 10 years earlier?].
    MMW Fortschr Med; 2002 Aug; 144(33-34):55. PubMed ID: 12380149
    [No Abstract]   [Full Text] [Related]  

  • 12. [How can lipid therapy be improved? Cardiologists insist on dual cholesterol inhibition].
    MMW Fortschr Med; 2005 Nov; 147(45):54. PubMed ID: 16320655
    [No Abstract]   [Full Text] [Related]  

  • 13. [For coronary disease patients is certain: the lower the LDL the better].
    MMW Fortschr Med; 2006 Jun; 148(24):6. PubMed ID: 16850797
    [No Abstract]   [Full Text] [Related]  

  • 14. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
    Nissen SE; Tuzcu EM; Schoenhagen P; Crowe T; Sasiela WJ; Tsai J; Orazem J; Magorien RD; O'Shaughnessy C; Ganz P;
    N Engl J Med; 2005 Jan; 352(1):29-38. PubMed ID: 15635110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of randomized study: intensive lipid lowering treatment stops coronary atherosclerosis].
    MMW Fortschr Med; 2004 Mar; 146(13):64-5. PubMed ID: 15219142
    [No Abstract]   [Full Text] [Related]  

  • 16. Cholesterol: low is good. Lower is better. PROVE IT has doctors rethinking how to treat high cholesterol and what's a good target.
    Harv Heart Lett; 2004 May; 14(9):3. PubMed ID: 15153372
    [No Abstract]   [Full Text] [Related]  

  • 17. [Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly].
    MMW Fortschr Med; 2005 Aug; 147(33-34):50-1. PubMed ID: 16138640
    [No Abstract]   [Full Text] [Related]  

  • 18. [Decreasing LDL level moderately or drastically. Is differential therapy with statins available? (interview by Dirk Einecke)].
    März W
    MMW Fortschr Med; 2004 Jul; 146(27-28):53. PubMed ID: 15526673
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of atorvastatin (80 mg/day) versus pravastatin (40 mg/day) on arterial remodeling at coronary branch points (from the REVERSAL study).
    Nicholls SJ; Tuzcu EM; Schoenhagen P; Sipahi I; Crowe T; Kapadia S; Nissen SE
    Am J Cardiol; 2005 Dec; 96(12):1636-9. PubMed ID: 16360349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.